Back to results
US 2023/0212201 A1Published application
Stat3 degraders and uses thereof
AssigneeKymera Therapeutics, Inc.
InventorsChris DE SAVI, Chris HO
Life of this patent
Estimating the term…
Abstract
The present invention relates to STAT3 degraders, their liquid formulations, and methods of use thereof for treating cancer.
Claims19
A liquid formulation comprising Compound A, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient and/or carrier;
- wherein Compound A is (2-(((5S,8S, 10aR)-3-acetyl-8-(((S)-5-amino-1-(2-chloro-3-(4-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutyl)phenoxy)-5-oxopentan-2-yl)carbamoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocin-5-yl)carbamoyl)-1H-indole-5-carbonyl)phosphonic acid.
Dependencies are inferred from the claim text.